USPSTF: Evidence Lacking for Screening for Eating Disorders
Evidence insufficient to support a recommendation for or against screening adults, teens for eating disorders
Evidence insufficient to support a recommendation for or against screening adults, teens for eating disorders
Evidence insufficient to evaluate the benefits and harms of screening for eating disorders in adolescents and adults
n August 2018, the Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) stating the application required additional data to further assess the efficacy and tolerability of dasotraline.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for dasotraline (Sunovion) in the treatment of binge eating disorder.
The results from this trial follow similar positive findings from a flexible-dose study of dasotraline.